ADVANCED TARGETING SYSTEMS

Company Information
Address 10451 ROSELLE ST STE 102
SAN DIEGO, CA, 92121-1209

http://www.ATSbio.com

Information

DUNS: 010081909

# of Employees: 9


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Enhancing CRISPR-based Therapeutic Interventions Via a Targeted Platform Tool

    Amount: $150,000.00

    Enhancing CRISPR based Therapeutic Interventions Via a Targeted Platform Tool Project Summary The approach described in this proposal anticipates the needs of translational drug development by design ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  2. Targeting a Poor Prognosis Marker for Tumor Therapy

    Amount: $150,480.00

    DESCRIPTION (provided by applicant): Targeting a Poor Prognosis Marker for Tumor Therapy Summary The purpose of this proposal is to develop a medical treatment for the elimination of metastatic ca ...

    SBIRPhase I2010Department of Health and Human Services
  3. Selective Activation in Specific Neuronal Populations

    Amount: $99,175.00

    DESCRIPTION (provided by applicant): Selective Activation in Specific Neuronal Populations Summary: Molecules targeted towards cell surface markers have been used for years to identify specific cell t ...

    SBIRPhase I2009Department of Health and Human Services
  4. Inhibition of Neurotransmission in Specific Neuronal Populations

    Amount: $114,336.00

    DESCRIPTION (provided by applicant): In extensive work over the last decade, it has become clear that biologically active molecules can be inserted into specific cell types through targeting to molec ...

    SBIRPhase I2008Department of Health and Human Services
  5. Drug Development of a Chronic Pain Therapeutic

    Amount: $0.00

    DESCRIPTION (provided by applicant): SP-SAP, a conjugate between the peptide neurotransmitter substance P, and the ribosome-inactivating protein, saporin, has been shown, through previous NIH funding, ...

    SBIRPhase I2003Department of Health and Human Services
  6. Drug Development of a Chronic Pain Therapeutic

    Amount: $2,388,923.00

    DESCRIPTION (provided by applicant): SP-SAP, a conjugate between the peptide neurotransmitter substance P, and the ribosome-inactivating protein, saporin, has been shown, through previous NIH funding, ...

    SBIRPhase II2003Department of Health and Human Services
  7. Monoclonal Antibodies to Target Neuronal Populations

    Amount: $0.00

    N/A

    SBIRPhase I2003Department of Health and Human Services
  8. Monoclonal Antibodies to Target Neuronal Populations

    Amount: $798,353.00

    N/A

    SBIRPhase II2003Department of Health and Human Services
  9. Targeting Neurons Involved in Chronic Pain Transmission

    Amount: $133,547.00

    DESCRIPTION (Adapted from applicant's abstract): Chronic pain is an enormous problem in the United States: it is estimated that 30 to 100 million people suffer from it. Often, current ...

    SBIRPhase I2001Department of Health and Human Services
  10. TOXICOLOGY/SAFETY STUDIES OF A CHRONIC PAIN THERAPEUTIC

    Amount: $397,984.00

    N/A

    SBIRPhase II2001Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government